HRP20240926T1 - Claudin-6-specifični imunoreceptori i epitopi t stanica - Google Patents
Claudin-6-specifični imunoreceptori i epitopi t stanica Download PDFInfo
- Publication number
- HRP20240926T1 HRP20240926T1 HRP20240926TT HRP20240926T HRP20240926T1 HR P20240926 T1 HRP20240926 T1 HR P20240926T1 HR P20240926T T HRP20240926T T HR P20240926TT HR P20240926 T HRP20240926 T HR P20240926T HR P20240926 T1 HRP20240926 T1 HR P20240926T1
- Authority
- HR
- Croatia
- Prior art keywords
- cancer
- nucleic acid
- seq
- amino acid
- acid sequence
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 20
- 150000007523 nucleic acids Chemical class 0.000 claims 20
- 102000039446 nucleic acids Human genes 0.000 claims 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims 16
- 102000003859 Claudin-6 Human genes 0.000 claims 9
- 108090000229 Claudin-6 Proteins 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 206010061252 Intraocular melanoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 241000713666 Lentivirus Species 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 1
- 201000005746 Pituitary adenoma Diseases 0.000 claims 1
- 206010061538 Pituitary tumour benign Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 201000005969 Uveal melanoma Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 201000005188 adrenal gland cancer Diseases 0.000 claims 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 230000005754 cellular signaling Effects 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000030381 cutaneous melanoma Diseases 0.000 claims 1
- 210000000750 endocrine system Anatomy 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 210000004392 genitalia Anatomy 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000026037 malignant tumor of neck Diseases 0.000 claims 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 206010027191 meningioma Diseases 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 201000002575 ocular melanoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000003913 parathyroid carcinoma Diseases 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 208000021310 pituitary gland adenoma Diseases 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 201000007444 renal pelvis carcinoma Diseases 0.000 claims 1
- 201000011453 reproductive organ cancer Diseases 0.000 claims 1
- 208000015608 reproductive system cancer Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000003708 skin melanoma Diseases 0.000 claims 1
- 201000002314 small intestine cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2014000868 | 2014-04-01 | ||
| EP2014072864 | 2014-10-24 | ||
| EP20160141.6A EP3708579B1 (en) | 2014-04-01 | 2015-03-30 | Claudin-6-specific immunoreceptors and t cell epitopes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240926T1 true HRP20240926T1 (hr) | 2024-10-11 |
Family
ID=52745896
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240926TT HRP20240926T1 (hr) | 2014-04-01 | 2015-03-30 | Claudin-6-specifični imunoreceptori i epitopi t stanica |
| HRP20190472TT HRP20190472T4 (hr) | 2014-04-01 | 2015-03-30 | Klaudin-6 specifični imunoreceptori i t-stanični epitopi |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20190472TT HRP20190472T4 (hr) | 2014-04-01 | 2015-03-30 | Klaudin-6 specifični imunoreceptori i t-stanični epitopi |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US10370423B2 (enExample) |
| EP (3) | EP3514172B1 (enExample) |
| JP (3) | JP6726656B2 (enExample) |
| CN (3) | CN113150109A (enExample) |
| AU (3) | AU2015239683B2 (enExample) |
| CA (1) | CA2942459C (enExample) |
| CY (1) | CY1121539T1 (enExample) |
| DK (3) | DK3126381T4 (enExample) |
| ES (3) | ES2982838T3 (enExample) |
| FI (1) | FI3708579T3 (enExample) |
| HR (2) | HRP20240926T1 (enExample) |
| HU (3) | HUE044515T2 (enExample) |
| LT (2) | LT3126381T (enExample) |
| ME (1) | ME03407B (enExample) |
| MX (1) | MX376026B (enExample) |
| PL (3) | PL3514172T3 (enExample) |
| PT (3) | PT3126381T (enExample) |
| RS (2) | RS65784B1 (enExample) |
| SI (3) | SI3126381T2 (enExample) |
| SM (1) | SMT201900262T1 (enExample) |
| WO (1) | WO2015150327A1 (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202110692WA (en) * | 2009-11-11 | 2021-12-30 | Ganymed Pharmaceuticals Gmbh | Antibodies specific for claudin 6 (cldn6) |
| CN104662044B (zh) | 2012-08-24 | 2018-10-30 | 加利福尼亚大学董事会 | 用于治疗ror1癌症并抑制转移的抗体和疫苗 |
| US10053511B2 (en) | 2013-11-06 | 2018-08-21 | Abbvie Stemcentrx Llc | Anti-claudin antibodies and methods of use |
| MA40921A (fr) * | 2014-11-05 | 2017-09-12 | Abbvie Stemcentrx Llc | Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation |
| JP6666342B2 (ja) | 2014-11-14 | 2020-03-13 | アメリカ合衆国 | 抗サイログロブリンｔ細胞レセプター |
| CN106146666B (zh) * | 2015-03-26 | 2019-09-06 | 科济生物医药（上海）有限公司 | 靶向cldn6的免疫效应细胞及其制备方法和应用 |
| WO2016180467A1 (en) | 2015-05-11 | 2016-11-17 | Biontech Cell & Gene Therapies Gmbh | Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination |
| WO2016180468A1 (en) | 2015-05-11 | 2016-11-17 | Biontech Cell & Gene Therapies Gmbh | Claudin-18.2-specific immunoreceptors and t cell epitopes |
| IL303905A (en) | 2015-05-18 | 2023-08-01 | Tcr2 Therapeutics Inc | Compositions and methods for TCR programming using fusion proteins |
| CN107849148B (zh) | 2015-05-21 | 2023-09-19 | 哈普恩治疗公司 | 三特异性结合蛋白质及使用方法 |
| GB201607534D0 (en) * | 2016-04-29 | 2016-06-15 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520568D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd | Peptides |
| GB201520550D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201602918D0 (en) | 2016-02-19 | 2016-04-06 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
| CN114028549A (zh) | 2016-02-19 | 2022-02-11 | 伊玛提克斯生物技术有限公司 | 用于nhl和其他癌症免疫治疗的新型肽和肽组合物 |
| CN109641012A (zh) | 2016-06-07 | 2019-04-16 | 马克思-德布鲁克-分子医学中心亥姆霍兹联合会 | 与bcma结合的嵌合抗原受体和car-t细胞 |
| KR20240113990A (ko) | 2016-06-27 | 2024-07-23 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 암 치료 조합 |
| MX2018015853A (es) | 2016-07-14 | 2019-08-21 | Genmab As | Anticuerpos multiespecificos frente a los grupos de diferenciacion 40 y 137 (cd40 y cd137). |
| ES2875959T3 (es) * | 2016-10-07 | 2021-11-11 | Tcr2 Therapeutics Inc | Composiciones y métodos para reprogramación de receptores de linfocitos T mediante el uso de proteínas de fusión |
| US12269859B2 (en) | 2016-12-02 | 2025-04-08 | Angeles Therapeutics, Inc. | Synthetic immune receptors and methods of use thereof |
| EP3595708A4 (en) * | 2017-03-15 | 2020-12-16 | Fred Hutchinson Cancer Research Center | HIGH AFFINITY MAGE-A1 SPECIFIC TCRS AND THEIR USES |
| SG11201908659RA (en) * | 2017-03-27 | 2019-10-30 | Noile Immune Biotech Inc | Chimeric antigen receptor |
| AU2018309339C1 (en) | 2017-08-04 | 2025-08-21 | BioNTech SE | Binding agents binding to PD-L1 and CD137 and use thereof |
| JP7599332B2 (ja) * | 2017-09-18 | 2024-12-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | クローディン６抗体及びがんを治療するための方法 |
| JP7273716B2 (ja) | 2017-09-29 | 2023-05-15 | 第一三共株式会社 | 抗体－ピロロベンゾジアゼピン誘導体コンジュゲート |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| CN120983617A (zh) | 2018-11-06 | 2025-11-21 | 健玛保 | 抗体配制剂 |
| WO2020097530A2 (en) * | 2018-11-09 | 2020-05-14 | Fred Hutchinson Cancer Research Center | Immunotherapy targeting mesothelin |
| EP4198057A1 (en) * | 2018-12-05 | 2023-06-21 | F. Hoffmann-La Roche AG | Diagnostic methods and compositions for cancer immunotherapy |
| SI3920939T1 (sl) * | 2019-02-08 | 2025-03-31 | Biontech Cell & Gene Therapies Gmbh | Celice, modificirane s himernim antigenskim receptorjem, za zdravljenje cldn6-izražajočih rakov |
| CA3132072A1 (en) * | 2019-03-01 | 2020-09-10 | Gritstone Bio, Inc. | Selection of t cell receptors |
| ES3017207T3 (en) | 2019-03-20 | 2025-05-12 | Univ California | Claudin-6 antibodies and drug conjugates |
| WO2021129927A1 (en) * | 2019-12-23 | 2021-07-01 | Biontech Cell & Gene Therapies Gmbh | Treatment with immune effector cells engineered to express an antigen receptor |
| EP4100059A1 (en) | 2020-02-04 | 2022-12-14 | Genmab A/S | Antibodies for use in therapy |
| KR20230107281A (ko) | 2020-11-11 | 2023-07-14 | 비온테크 에스이 | 프로그램된 사멸-1 단백질에 대한 모노클로날 항체 및 의약에서의 용도 |
| US20240216427A1 (en) * | 2020-12-30 | 2024-07-04 | St. Jude Children's Research Hospital, Inc. | Chimeric antigen receptors targeting splice variants of the extracellular matrix proteins tenascin c (tnc) and procollagen 11a1 (col11a1) |
| TW202315891A (zh) | 2021-06-21 | 2023-04-16 | 丹麥商珍美寶股份有限公司 | 結合劑給藥排程 |
| JP2024525758A (ja) | 2021-07-13 | 2024-07-12 | ビオンテック・ソシエタス・エウロパエア | がんのための併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性結合剤 |
| EP4395823A4 (en) * | 2021-09-03 | 2025-07-16 | Novarock Biotherapeutics Ltd | BISPECIFIC BINDING PROTEINS THAT BIND TO CD137 AND A TUMOR-ASSOCIATED ANTIGEN |
| EP4412714A1 (en) | 2021-10-06 | 2024-08-14 | Genmab A/S | Multispecific binding agents against pd-l1 and cd137 in combination with anti pd-1 antibodies for treating cancers |
| IL311771A (en) | 2021-10-06 | 2024-05-01 | BioNTech SE | Multispecific binding agents against pd-l1 and cd137 in combination |
| CA3234897A1 (en) * | 2021-10-14 | 2023-04-20 | Kunle Odunsi | Compositions and methods for use of recombinant t cell receptors against claudin 6 |
| EP4522654A1 (en) | 2022-05-12 | 2025-03-19 | BioNTech SE | Monoclonal antibodies directed against programmed death-1 protein and their use in medicine |
| EP4522657A1 (en) | 2022-05-12 | 2025-03-19 | Genmab A/S | Binding agents capable of binding to cd27 in combination therapy |
| CN119365215A (zh) | 2022-05-12 | 2025-01-24 | 健玛保 | 在组合疗法中能够结合cd27的结合剂 |
| CN115232207B (zh) * | 2022-05-19 | 2023-06-13 | 河南大学 | 抗体-溶菌素（SM-ScFv-Fc-Ly）在治疗变形链球菌感染中的应用 |
| WO2024165057A1 (en) * | 2023-02-07 | 2024-08-15 | LaNova Medicines Limited | Antibodies and antibody-drug conjugates targeting claudin 6 |
| WO2024209072A1 (en) | 2023-04-06 | 2024-10-10 | Genmab A/S | Multispecific binding agents against pd-l1 and cd137 for treating cancer |
| US12403202B2 (en) | 2023-05-25 | 2025-09-02 | The Regents Of The University Of California | Dosage of claudin-6 conjugates for cancer treatment |
| WO2025114541A1 (en) | 2023-11-30 | 2025-06-05 | Genmab A/S | Antibodies capable of binding to ox40 in combination therapy |
| WO2025184170A1 (en) | 2024-02-27 | 2025-09-04 | Overt Bio, Inc. | Methods and compositions for improving t cell function in an immunosuppressive environment |
| CN118812714B (zh) * | 2024-08-21 | 2025-05-27 | 广州百吉生物制药有限公司 | 一种紧密连接蛋白抗体b3及其应用 |
| CN119320451B (zh) * | 2024-08-21 | 2025-05-16 | 百吉生物医药(广州)股份有限公司 | 一种紧密连接蛋白抗体d03及其应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5677139A (en) | 1995-04-21 | 1997-10-14 | President And Fellows Of Harvard College | In vitro differentiation of CD34+ progenitor cells into T lymphocytes |
| EP0871747A1 (en) | 1996-01-02 | 1998-10-21 | Chiron Viagene, Inc. | Immunostimulation mediated by gene-modified dendritic cells |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7435596B2 (en) * | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| JP2009508517A (ja) * | 2005-09-22 | 2009-03-05 | コーエン，イルン，アール | Ｔ細胞受容体定常ドメインの免疫原性断片及びそれに由来するペプチド |
| CA2672581A1 (en) | 2006-12-14 | 2008-06-19 | Forerunner Pharma Research Co., Ltd. | Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same |
| EP2138576A4 (en) * | 2007-03-16 | 2011-02-23 | Kyowa Hakko Kirin Co Ltd | ANTI-CLAUDIN-4 ANTIBODY |
| CA2711557A1 (en) * | 2008-01-11 | 2009-07-16 | The University Of Tokyo | Anti-cldn6 antibody |
| DK2398902T3 (da) * | 2009-02-20 | 2023-12-04 | Astellas Pharma Inc | Fremgangsmåder og sammensætninger til diagnosticering og behandling af cancer |
| SG10202110692WA (en) * | 2009-11-11 | 2021-12-30 | Ganymed Pharmaceuticals Gmbh | Antibodies specific for claudin 6 (cldn6) |
| EP2322555A1 (en) * | 2009-11-11 | 2011-05-18 | Ganymed Pharmaceuticals AG | Antibodies specific for claudin 6 (CLDN6) |
| EP2547695B1 (en) * | 2010-03-16 | 2018-05-09 | Biontech Protein Therapeutics GmbH | Tumor vaccination involving a humoral immune response against self-protein cldn18.2 |
| CN102971421A (zh) * | 2010-04-13 | 2013-03-13 | 西格马-奥尔德里奇有限责任公司 | 产生内源标记的蛋白的方法 |
| EP2404936A1 (en) * | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
| ES2754394T3 (es) * | 2010-09-08 | 2020-04-17 | Chemotherapeutisches Forschungsinstitut Georg Speyer Haus | Receptores de antígenos quiméricos con una región bisagra optimizada |
| MX341147B (es) * | 2011-05-13 | 2016-08-09 | Ganymed Pharmaceuticals Ag | Anticuerpos para el tratamiento del cáncer que expresa cldn6. |
| SG11201404285VA (en) | 2012-02-22 | 2014-10-30 | Univ Pennsylvania | Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer |
-
2015
- 2015-03-30 SI SI201530629T patent/SI3126381T2/sl unknown
- 2015-03-30 HU HUE15712657 patent/HUE044515T2/hu unknown
- 2015-03-30 PT PT15712657T patent/PT3126381T/pt unknown
- 2015-03-30 HR HRP20240926TT patent/HRP20240926T1/hr unknown
- 2015-03-30 CN CN202110278993.9A patent/CN113150109A/zh active Pending
- 2015-03-30 PT PT191512383T patent/PT3514172T/pt unknown
- 2015-03-30 AU AU2015239683A patent/AU2015239683B2/en active Active
- 2015-03-30 ME MEP-2019-67A patent/ME03407B/me unknown
- 2015-03-30 ES ES20160141T patent/ES2982838T3/es active Active
- 2015-03-30 SI SI201532019T patent/SI3708579T1/sl unknown
- 2015-03-30 RS RS20240864A patent/RS65784B1/sr unknown
- 2015-03-30 RS RS20190361A patent/RS58627B2/sr unknown
- 2015-03-30 PL PL19151238T patent/PL3514172T3/pl unknown
- 2015-03-30 HU HUE20160141A patent/HUE067504T2/hu unknown
- 2015-03-30 ES ES19151238T patent/ES2784537T3/es active Active
- 2015-03-30 US US15/124,640 patent/US10370423B2/en active Active - Reinstated
- 2015-03-30 DK DK15712657.4T patent/DK3126381T4/da active
- 2015-03-30 SI SI201531143T patent/SI3514172T1/sl unknown
- 2015-03-30 LT LTEP15712657.4T patent/LT3126381T/lt unknown
- 2015-03-30 DK DK20160141.6T patent/DK3708579T3/da active
- 2015-03-30 CA CA2942459A patent/CA2942459C/en active Active
- 2015-03-30 WO PCT/EP2015/056899 patent/WO2015150327A1/en not_active Ceased
- 2015-03-30 FI FIEP20160141.6T patent/FI3708579T3/fi active
- 2015-03-30 LT LTEP20160141.6T patent/LT3708579T/lt unknown
- 2015-03-30 DK DK19151238.3T patent/DK3514172T3/da active
- 2015-03-30 CN CN201580017607.3A patent/CN106459165B/zh active Active
- 2015-03-30 HR HRP20190472TT patent/HRP20190472T4/hr unknown
- 2015-03-30 EP EP19151238.3A patent/EP3514172B1/en active Active
- 2015-03-30 PL PL20160141.6T patent/PL3708579T3/pl unknown
- 2015-03-30 CN CN202110279207.7A patent/CN113150110A/zh active Pending
- 2015-03-30 EP EP15712657.4A patent/EP3126381B2/en active Active
- 2015-03-30 ES ES15712657T patent/ES2717530T5/es active Active
- 2015-03-30 PL PL15712657T patent/PL3126381T5/pl unknown
- 2015-03-30 MX MX2016012713A patent/MX376026B/es active IP Right Grant
- 2015-03-30 HU HUE19151238A patent/HUE050355T2/hu unknown
- 2015-03-30 SM SM20190262T patent/SMT201900262T1/it unknown
- 2015-03-30 PT PT201601416T patent/PT3708579T/pt unknown
- 2015-03-30 EP EP20160141.6A patent/EP3708579B1/en active Active
- 2015-03-30 JP JP2017503063A patent/JP6726656B2/ja active Active
-
2019
- 2019-04-02 CY CY20191100366T patent/CY1121539T1/el unknown
- 2019-06-18 US US16/444,510 patent/US11345731B2/en active Active
- 2019-07-31 AU AU2019210582A patent/AU2019210582B2/en active Active
-
2020
- 2020-02-19 JP JP2020025935A patent/JP6985440B2/ja active Active
-
2021
- 2021-05-31 AU AU2021203528A patent/AU2021203528B2/en active Active
- 2021-11-25 JP JP2021190855A patent/JP7451858B2/ja active Active
-
2022
- 2022-04-04 US US17/712,562 patent/US20220306711A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20240926T1 (hr) | Claudin-6-specifični imunoreceptori i epitopi t stanica | |
| FI3240805T3 (fi) | Cd19- ja cd20-vasteellinen bispesifinen tai-veräjän kimeerinen antigeenireseptori | |
| RU2018111462A (ru) | Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток | |
| HRP20220799T1 (hr) | Klaudin-18-2-specifični imunoreceptori i stanični epitopi t | |
| HRP20220131T1 (hr) | Nova terapija s t-staničnim receptorima i imunološka terapija koja koristi iste | |
| IL264144B1 (en) | Antibody 18a2 against claudin and its use | |
| RU2017121892A (ru) | Клетка | |
| JP2016534717A5 (enExample) | ||
| JP2018529327A5 (enExample) | ||
| RU2018107802A (ru) | Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин | |
| JP2018506981A5 (enExample) | ||
| JP2011157397A5 (enExample) | ||
| JP2019531084A5 (enExample) | ||
| FI4063397T3 (fi) | Yksidomeenivasta-aineisiin perustuvia antigeenireseptoreita ja menetelmiä niiden käyttämiseksi | |
| JP2018523493A5 (enExample) | ||
| JP2020510422A5 (enExample) | ||
| RU2017112882A (ru) | Химерные рецепторы антигенов | |
| JP2020500530A5 (enExample) | ||
| HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene | |
| JP2019513347A5 (enExample) | ||
| FI3546572T3 (fi) | Cd19-spesifinen kimeerinen antigeenireseptori ja sen käyttötapoja | |
| JP2018509175A5 (enExample) | ||
| RU2018113510A (ru) | Химерные рецепторы антигена, нацеленные на psca | |
| RU2018106452A (ru) | Поливалетные и полиспецифичные gitr-связывающие слитые белки | |
| RU2016138422A (ru) | Химерный антигенный рецептор |